课题基金 / 基金详情

Translating cystic fibrosis gene-addition therapy for use in human lungs: Demonstrating efficacy, safety and scalability

Translating cystic fibrosis gene-addition therapy for use in human lungs: Demonstrating efficacy, safety and scalability
将囊性纤维化基因添加疗法应用于人肺:展示有效性、安全性和可扩展性
批准号:
nhmrc : GNT1160011
负责人:
金额:
$86.13万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2019
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2019-01-01 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Expensive drugs like Kalydeco can improve cystic fibrosis (CF) lung health, but only in some patients. Airway gene-addition therapy could treat any patient. Our successful airway gene therapy method could not be tested in CF lungs until our recent development of rats with CF. This project will precisely-target our gene therapy to lung regions, assess the effectiveness and safety with techniques including our revolutionary X-ray methods, and test its potential in the human-size lungs of sheep
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金